TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04098276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeWomen Plus technology based intervention
Description: The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeWomen Plus technology based intervention
Description: The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeWomen Plus technology based intervention
Description: The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
Study: NCT06250062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized IL-17A Monoclonal Antibody（JS005）
Description: Injection
Study: NCT05823766

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood Draw for Plasma, DNA, Serum, RNA
Study: NCT06109779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig IV (intravenous) Q3W
Study: NCT06250062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized IL-17A Monoclonal Antibody（JS005）
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo（JS005）
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo（JS005）
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo（JS005）
Description: Injection
Study: NCT05823766

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood Draw for Plasma, DNA, Serum, RNA

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood Draw for Plasma, DNA, Serum, RNA

Intervention type: PROCEDURE
Intervention: EEG
Description: An EEG will be performed on patients who screen positive for PTE at the clinical visit

Intervention type: PROCEDURE
Intervention: EEG
Description: An EEG will be performed on patients who screen positive for PTE at the clinical visit

Intervention type: BEHAVIORAL
Intervention: Telephone Outcome Assessment
Description: Assessments will be administered over the telephone to evaluate participant outcome status and screen for PTE
Study: NCT06109779

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (intravenous) Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine (Oral) 1250 mg/m2 BID (twice daily) for 2 weeks on/1 week off in 21-day cycles or per local practice
Study: NCT04942405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TURCOVAC
Description: Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) experimental vaccine at the schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: Two doses at 28-day interval, each inoculation dose is 0.5 mL. Two doses of dosage (vaccine contains 600 subunit of SARS-CoV-2 virus antigen) vaccine at the schedule of day 0, 28
Study: NCT06583564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG lymphangiography procedure
Description: All patients underwent standard complete mesocolic excision (CME) or total mesorectal excision (TME) with curable purpose using ICG lymphangiography procedure
Study: NCT06583967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Group 1 - Elliptical Trainer Group 2 - Treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Training
Description: Group 1 - Elliptical Trainer Group 2 - Treadmill
Study: NCT05159570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Commercially available ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Isocaloric placebo
Study: NCT04657133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham RIC will be performed by the same electric autocontrol device with cuff placed on arm. Sham RIC procedures consist of five cycles of 5-min inflation (30 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 7 days after enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard medication therapy
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study: NCT06383663

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular lymph node dissection combined with radiotherapy
Description: Breast cancer patients in the expreimental cohort with only ipsilateral supraclavicular lymph node metastasis were first treated with supraclavicular lymph node dissection and received standard radiotherapy after surgery.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Patients in the control group received only standard radiation therapy.
Study: NCT06109779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine/Cisplatin IV (Intravenous) 1000 mg/m2 plus cisplatin 25 mg/m2 on Day 1 and Day 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 [Tegafur/Oteracil/gimeracil]
Description: S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-1 [Tegafur/Oteracil/gimeracil]
Description: S-1 \[Tegafur/Oteracil/gimeracil\] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles
Study: NCT06306417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: lifestyle intervention

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: lifestyle intervention
Description: lifestyle intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture
Study: NCT06128356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Sublingual
Description: Dexmedetomidine 120 mcg on two thin dissolvable films for sublingual administration
Study: NCT05794347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traction
Description: Continuous mechanical traction will be applied to the lumbar area in 2 different positions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traction
Description: Continuous mechanical traction will be applied to the lumbar area in 2 different positions.
Study: NCT04832243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each version of the questionnaire includes a different number of true-false statements that study participants are asked to identify.
Study: NCT06256861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: This group is given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study: NCT04499521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrachyGel VHPS
Description: Packing system for administering brachytherapy in cervical cancer patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrachyGel VHPS
Description: Packing system for administering brachytherapy in cervical cancer patients
Study: NCT06205225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text4HF
Description: Behavioral text messages about heart failure self-care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyApps
Description: consumer mobile health apps and devices for heart failure self-care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyApps & Text4HF
Description: Consumer mobile health apps and devices supplemented with behavioral text messages for heart failure self-care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants assigned to the enhanced usual care group will receive (1) standard care, (2) patient education about HF self-care, and (3) three connected health devices (Withings weight scale and blood pressure monitor, and Fitbit activity tracker with Fitbit mobile app).
Study: NCT05421689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
Description: The study will treat 66 patients at 2 clinical sites: UC Davis Center for Voice and Swallowing and UCSF Voice and Swallowing Center. Patients will be randomized 1:1 to receive either 2 AMDC-GIR doses of 150 x 10⁶ cells or 2 doses of identical placebo composed of the same cryopreservation medium used for AMDC-GIR. Enrollment is expected to be completed within 2 years of initiating the study. Patients will be followed for 24 months post-treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: two doses of placebo will be administered and spaced 4-6 weeks apart.
Study: NCT05079698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Intravenous (IV) infusion of 177Lu-PSMA-617 on Day 1 of treatment Cycles 1 and 2. PSMA PET utilizing either the 68Ga-PSMA-11 or 18F-DCFPyL tracer is acceptable. Patients should be restaged using the same tracer which was utilized to establish initial eligibility for the trial.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: No later than 5 weeks (+/- 7 days) after the 2nd cycle of 177Lu-PSMA-617, patients will then undergo SBRT (900 cGy x 3 fractions).
Study: NCT05907343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham TBS
Description: A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a sham coil when its output indicates that the participant is not properly engaged in the video game.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop TBS
Description: A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. The BCI delivers TBS with a real coil when its output indicates that the participant is not properly engaged in the video game.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop TBS
Description: A BCI records and analyzes the participant's EEG as they perform cognitively demanding video game tasks. TBS with the real coil is delivered irrelevant of the BCI decoder output.
Study: NCT05309395

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FoodRx
Description: Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FoodRx
Description: Participants will receive weekly meal plans and recipes and the groceries required to prepare the recommended meals
Study: NCT05013203

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue culture
Description: Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue culture
Description: Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic

Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue culture
Description: Discarded tissue collected during surgery will be sent to the hospital microbiological lab for aerobic and anaerobic

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: Discarded tissue collected during surgery will be sent to an outside lab for testing using next generation sequencing (NGS)
Study: NCT05383456

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test
Description: Standard diagnostic tests.

Intervention type: DRUG
Intervention: HIV Anti-retroviral Background Therapy
Description: All participants are required be on continuous HIV Anti-retroviral Background Therapy.~No intervention on drug is part of the Study.
Study: NCT06451081

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief cessation advice
Description: Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cessation advice
Description: Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cessation advice
Description: Participants will receive brief cessation advice following the AWARD (ask, warn, advise, refer, do-it-again) model:~A: Ask about the tobacco use status; W: Warn about the hazards of tobacco use; A: Advise the smokers to quit; R: Refer the smokers to cessation services; D: Do-it-again

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out active referral
Description: Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out active referral
Description: Participants will be automatically referred to a smoking cessation service upon joining the trial, unless they choose to opt out. Contacts of participants will be delivered to a service provider of their choice or based on their living district and preferred treatment modality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economic mobile messaging
Description: Participants will receive behavioural economics-informed messages via mobile instant messaging for 3 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opt-in active referral
Description: Participants will be offered a referral to a smoking cessation service. Contacts of participants who opt-in will be delivered to a service provider of their choice
Study: NCT04706728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to playlists with music prior to-, during and after the ECT procedure
Description: Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first four weeks of their ECT treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to playlists with music prior to-, during and after the ECT procedure
Description: Patients choose between two expert-curated playlists with music one day prior to ECT procedures for the first two weeks of their ECT treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure
Description: Patients choose between two expert-curated playlists with sounds from nature one day prior to ECT procedures for the first two weeks of their ECT treatment
Study: NCT05901883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEL383
Description: Subjects will receive CEL383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo
Study: NCT06328933

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.